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Introduction
Chronic obstructive pulmonary disease (COPD) is a growing
global epidemic condition with raising morbidity and mortality 
as population age. It has been projected that COPD, which 
ranked sixth as the cause of death in 1990, will become the third 
leading cause of death worldwide by 2020 [1]. Smoking is the 
most well-known risk factor for COPD; however, non-smokers 
may develop chronic airflow obstruction through occupational 
exposure to dust and chemicals and indoor pollution from 
biomass. Other recognized risk factors are genetic predisposition 
and low socioeconomic status [1].
COPD is characterized by progressive airflow limitation 
from remodeling of small airways and destruction of lung 
parenchyma. In addition to local pulmonary injury, it has been 
increasingly recognized that COPD carries significant extra 
pulmonary effects that may contribute to the severity of disease 
in individual patients [2]. For example, COPD is associated 
with cardiovascular diseases, osteoporosis, diabetes, and 
metabolic syndrome more frequently than expected from 
common etiological factors such as smoking, suggesting a causal 
association between these comorbidities and the systemic 
effects of COPD.  This is a topic of increasing interest given the 
large burden of hospitalizations and mortality associated with 
this condition [3]. The mechanisms linking COPD to systemic 
manifestations and comorbidities remains unelucidated, but a 
potential mechanism is systemic inflammation [2].
Proposed mechanisms of systemic inflammation in COPD 
include systemic oxidative stress, activation of circulating 
inflammatory cells and increased levels of circulating 
inflammatory cytokines [4, 5]. Inflammation in COPD involves 
both innate immunity (neutrophils, macrophages, eosinophils, 
mast cells, natural killer cells, gamma delta T cells, and 
dendritic cells) and adaptive immunity (T and B lymphocytes), 
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but also involves the activation of airway and alveolar epithelial 
cells, endothelial cells, and fibroblasts. Cigarette smoke and 
other irritants activate the release of multiple chemotactic 
mediators, which attract circulating neutrophils, monocytes, 
and lymphocytes into the lungs [4, 5]. Irritant-activated 
epithelial cells produce inflammatory mediators, including 
tumor necrosis factor (TNF) alpha, interleukin (IL)-1 beta, 
IL-6, granulocyte-macrophage colony-stimulating factor 
(GM-CSF), and IL-8. This inflammation persists even when 
smoking is stopped, suggesting that there are self-perpetuating 
mechanisms, although these have yet to be identified [6, 7]. It 
is possible that memory T cells, bacterial colonization, and/or 
autoimmunity may drive persistent inflammation in COPD [7].
Several studies have explored the systemic inflammatory state 
in COPD by demonstrating elevated levels of inflammatory 
markers, inflammatory cells, and a variety of inflammatory 
mediators such as cytokines in the serum and sputum of patients 
with COPD [4, 8–16]. Based on our literature review, most 
studies measuring local inflammatory responses in COPD have 
been performed in induced sputum and not in bronchoalveolar 
lavage (BAL) samples such as in our study. Cytokines are 
extracellular signaling proteins that play important roles in 
inflammatory and immune responses. Depending on their 
effects promoting or inhibiting inflammatory mechanisms, 
cytokines are normally classified as proor anti-inflammatory, 
although it is not uncommon for many cytokines to exert both 
types of effects depending on a variety of factors or conditions. 
Chemokines are a family of structurally-related cytokines with 
chemo-attractant properties that play a central role in the 
recruitment of leukocytes to sites of inflammation. Elevated 
levels of several pro-inflammatory cytokines, including TNF-α, 
IL-1β, and IL-6; the chemokine IL-8, the anti-inflammatory 
cytokine IL-10 and vascular endothelial growth factor (VEGF) 
have been found to be elevated in the induced sputum of 
individuals with COPD [17]. A pattern of elevated serum levels 
of IL-6, IL-8, TNF-α, and VEGF has also been described in 
different studies. The combined elevation of these cytokines in 
the serum was shown to be significantly associated with severity 
of disease [14]. The exact role of each cytokine is not completely 
elucidated but some examples of studied effects are the skeletal 
muscle weakness associated with IL-6, cachexia associated with 
TNF-α and IL-1β and hypoxemia also associated with TNF-α 
[18].
A more profound and detailed understanding of local and 
systemic inflammatory responses in COPD is necessary in view 
of the growing interest in studying it as a systemic condition 
and in the search and development of new therapies [19]. The 
purpose of this study was to compare inflammatory cytokine 
profiles in the plasma and BAL of COPD and non-COPD 
subjects.
Methods
Study design and subjects
This was a pilot cross-sectional study analyzing the data of 
a subgroup of subjects included in the study “The Impact of 
Oxidative Stress on HIV-Induced Lung Disease” conducted at 
the University of Louisville in Louisville, Kentucky, USA. The 
study enrolled 132 subjects from February 2014 to October 2016 
and included HIV, non-HIV, COPD and non-COPD subjects. All 
participants provided written informed consent and the study 
was approved by the Institutional Review Board (IRB), approval 
# 13.0442. HIV subjects were excluded for the purposes of our 
study and 65 non-HIV subjects were selected; 31 with a diagnosis 
of COPD and 34 non-COPD controls. The diagnosis of COPD 
was made based on the current GOLD guidelines, defined as 
FEV1/FVC ratio of less than 0.70 [1]. All subjects were seen in an 
outpatient basis and were stable from a respiratory standpoint. 
They underwent spirometry, blood sample collection and 
outpatient bronchoscopy with BAL.
Spirometry
Spirometry was conducted following the guidelines of the 
American Thoracic Society. A post-bronchodilator forced 
expiratory volume in 1 second (FEV1)/forced vital capacity 
(FVC) < 0.7 confirmed airflow limitation and the diagnosis of 
COPD.
Samples
Serum: Venous blood (4cc) was collected using Vacutainer 
tubes and allowed to clot at room temperature. Following 
centrifugation at 300 x g for 10 min, the serum was separated by 
aspiration, aliquoted and stored frozen at -80°C until assayed.
Bronchoalveolar lavage: A bronchoscope was wedged into a 
distal segment of a bronchus. After the administration of local 
anesthesia (lidocaine 1% solution), a total of 180 ml of saline 
solution in three 60 ml aliquots were instilled into a lobe of the 
lung, with gentle aspiration after each aliquot. The lavage fluid 
was filtered through sterile gauze and then centrifuged at 
800 x g for 10 minutes. The cell pellet was resuspended in 
Hanks’ balanced salt solution and the supernatants aliquoted 
and stored at -80°C.
Cytokine measurements
Serum and BAL samples were thawed and centrifuged at 10,000 
x g for 5 minutes prior to use in the assays. The concentrations
of twenty-one different cytokines and chemokines in plasma
and BAL samples were measured using Milliplex MAP High 
Sensitivity Human T cell panel kits (HSCYTMAG-28SK, EMD 
Millipore, Billerica, MA) according to the manufacturer’s 
instructions. The measured cytokines/chemokines were: IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, 
IL-21, IL-23, IFN-γ, TNF-α, CCL3 (MIP-1α), CCL4 (MIP-1β), 
CCL20 (MIP-3α), CXCL11 (I-TAC) and CX3CL1 (Fractalkine). 
Cytokine/chemokine levels were reported in picogram per 
milliliter (pg/mL). Cytokine levels in the BAL fluid were adjusted 
for total protein to account for potential dilution.
Statistical analysis
Categorical variables were summarized with frequencies and 
percentages and differences between groups were tested using 
Chisquared or Fisher’s Exact tests. Continuous variables were 
summarized with medians and interquartile ranges and the 
Mann-Whitney U-test was used to test for differences between 
groups. We considered a two-sided p value < 0.05 as statistically 
significant. We used the software R version 3.3.2 for statistical 
analysis.
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Results
Subject Characteristics
The demographics and characteristics of the subjects are shown 
in Table 1. Sixty-five subjects were included in the study; 31 
with the diagnosis of COPD and 34 non-COPD controls. COPD 
subjects were overall older than non-COPD (median age 59 
vs 36; p = <0.001). History of bacterial pneumonia was more 
common in the COPD group (45% vs 15%; p = 0.013) as was 
the history of hypertension (55% vs 26%; p = 0.025). Groups 
were otherwise similar in respect to gender, smoking history 
and comorbidities such as asthma, diabetes and chronic kidney 
disease.
Table 1. Baseline Characteristics of the Study Subjects.
 
IQR: interquartile range; COPD: chronic obstructive pulmonary disease
FEV1: forced expiratory volume in one second; FVC: forced vital capacity
Cytokine Levels
Plasma cytokine levels are shown in Table 2. COPD subjects 
had significantly higher mean plasma levels of twelve of the 
twentyone measured cytokines: TNF-α, IL-8, IL-21, IL-7, 
IL-10, IFN-γ, IL-12p70, IL-2, IL-17A, IL-23, MIP-3α, and 
fractalkine. Levels of the remaining measured plasma cytokines 
in comparison to non-COPD subjects were not significantly 
different.
BAL fluid cytokine levels are shown in Table 3. None of the
twenty-one measured cytokines was found to have significantly
elevated levels in COPD subjects in comparison with non-COPD
subjects. Level of TNF-α was found to be significantly elevated 
in non-COPD subjects.
Table 2. Plasma Cytokine Levels 
(measured in Picogram per milliliter, pg/mL). 
IQR: interquartile range; COPD: chronic obstructive pulmonary disease IL: interleukin; TNF: tumor 
necrosis factor, GMSCF: granulocyte macrophage colony-stimulating factor MIP: macrophage 
inflammatory protein; I-TAC: interferon-inducible T-cell alpha chemoattractant; IFN: interferon
Table 3. Bronchoalveolar Lavage Cytokine Levels 
(measured in Picogram per milliliter, pg/mL, adjusted for total protein). 
IQR: interquartile range; COPD: chronic obstructive pulmonary disease IL: interleukin; TNF: tumor 
necrosis factor, GMSCF: granulocyte macrophage colony-stimulating factor MIP: macrophage 
inflammatory protein; I-TAC: interferon-inducible T-cell alpha chemoattractant; IFN: interferon
Correlation between cytokine level and pulmonary 
function
As shown in Table 4, BAL levels of GMSCF and TNF-α were 
positively correlated with FEV1/FVC. In the plasma, levels of 
fractalkine, IL-12p70, IL-17A, IL-2, IL-21, IL-6, IL-7, IL-8 and 
TNF-α were negatively correlated.
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COPD N=31 Non-COPD N=34 P-value
Pro-inflammatory IL-1β, Median (IQR) 1.4 (1.2) 1.1 (0.7) 0.053
IL-6 1.4 (1.9) 0.7 (0.9) 0.069
TNFα 6.5 (2.2) 3.7 (1.9) 0.005
IL-8 5.1 (2.6) 2.9 (2.3) 0.008
GMCSF 35 (43.9) 21 (36.8) 0.081
IL-21 1 (0.6) 0.4 (0.7) 0.006
IL-7 5.9 (1.6) 4.3 (2.4) 0.022
Anti-inflammatory IL-10 8.5 (6.1) 5.1 (2.9) 0.036
Chemokines MIP-1α 13.6 (5.3) 12.2 (7) 0.515
MIP-1β 10.06 (4.04) 8.82 (6.32) 0.144
MIP-3α 24.4 (14.6) 19.8 (13.1) 0.035
I-TAC 14.5 (22.4) 12.2 (17.1) 0.317
FRACTALKINE 68.9 (29.8) 34.3 (27) 0.011
Th1 IFN-γ 12.6 (11.8) 9 (6.9) 0.021
IL-12p70 1.8 (2.3) 0.7 (1.3) 0.025
IL-2 1.4 (1.6) 0.9 (0.6) 0.014
Th17 IL-17A 4.4 (5.2) 1.7 (5.1) 0.026
IL-23 34.7 (51.3) 11.3 (32.5) 0.026
Th2 IL-4 2.1 (8.8) 0 (3) 0.316
IL-5 1.4 (1.9) 0.7 (1.4) 0.245
IL-13 1.8 (3.8) 1.4 (2.5) 0.803
COPD N=31 Non-COPD N=34 P-value
Age, Median (IQR) 59 (11) 36 (22.5) <0.001
Sex: Male, n (%) 16 (52) 17 (50) >0.999
Current Smoker, n (%) 24 (77) 28 (82) 0.759
Alcohol Dependence or Abuse, n (%) 0 (0) 1 (3) >0.999
Asplenia, n (%) 1 (3) 1 (3) >0.999
History of Asthma, n (%) 12 (40) 12 (38) >0.999
History of Atelectasis, n (%) 0 (0) 0 (0) >0.999
History of Bacterial Pneumonia, n (%) 14 (45) 5 (15) 0.013
History of Bronchiectasis, n (%) 0 (0) 0 (0) >0.999
Cirrhosis, n (%) 1 (3) 0 (0) 0.477
Chronic Kidney Disease, n (%) 2 (6) 0 (0) 0.224
Dementia, n (%) 1 (3) 0 (0) 0.484
Diabetes Mellitus, n (%) 8 (26) 4 (12) 0.204
History of Gastric Reflux, n (%) 10 (33) 7 (21) 0.272
History of Hepatitis B, n (%) 1 (3) 1 (3) >0.999
History of Hepatitis C, n (%) 6 (19) 3 (9) 0.29
Home oxygen use, n (%) 8 (30) 1 (9) 0.237
Hypercholesterolemia, n (%) 5 (16) 4 (12) 0.726
Hypertension, n (%) 17 (55) 9 (26) 0.025
Hypertriglyceridemia, n (%) 4 (13) 1 (3) 0.184
Hypothyroidism, n (%) 3 (10) 2 (6) 0.659
Inflammatory Bowel Disease, n (%) 0 (0) 0 (0) >0.999
Presence of Lipodystrophy, n (%) 0 (0) 0 (0) >0.999
Peripheral Neuropathy, n (%) 5 (16) 3 (9) 0.463
Other Neurological Disease, n (%) 2 (6) 1 (3) 0.602
History of Pneumothorax, n (%) 0 (0) 1 (3) >0.999
FEV1/FVC, Median (IQR) 0.6 (0.1) 0.8 (0.1) <0.001
FEV1 (liters), Median (IQR) 1.9 (1.2) 3.1 (1.2) <0.001
COPD N=31 Non-COPD N=34 P-value
Pro-inflammatory IL-1β, Median (IQR) 0 (0) 0 (0) 0.923
IL-6 0.013 (0.03) 0.016 (0.04) 0.623
TNFα 0.002 (0) 0.006 (0.01) 0.009
IL-8 0.534 (0.52) 0.285 (0.47) 0.198
GMCSF 0.006 (0) 0.007 (0.01) 0.195
IL-21 0 (0) 0 (0) 0.415
IL-7 0 (0) 0 (0.02) 0.210
Anti-inflammatory IL-10 0 (0) 0 (0) 0.497
Chemokines MIP-1α 0.023 (0.02) 0.028 (0.03) 0.893
MIP-1β 0 (0.01) 0.005 (0.02) 0.168
MIP-3α 0 (0.03) 0.018 (0.13) 0.172
I-TAC 0 (0.02) 0.003 (0.02) 0.961
FRACTALKINE 0 (0) 0 (0.1) 0.097
Th1 IFN-γ 0 (0) 0 (0) 0.154
IL-12p70 0 (0) 0 (0) 0.149
IL-2 0 (0) 0 (0) 0.699
Th17 IL-17A 0 (0) 0 (0) 0.221
IL-23 0 (0) 0 (0) 0.221
Th2 IL-4 0.012 (0.04) 0 (0.01) 0.230
IL-5 0 (0) 0 (0) 0.330
IL-13 0 (0) 0 (0) 0.154
Table 4. Correlation between cytokine level and FEV1/FVC. 
BAL: bronchoalveolar lavage; GMSCF: granulocyte macrophage colony-stimulating factor; IL: 
interleukin; TNF: tumor necrosis factor
BAL levels of GMSCF, IFN-γ, IL-17A and TNF-α were positively 
correlated with FEV1. In the plasma, levels of Fractalkine, IL-8 
and TNF-α were negatively correlated with FEV1. This is shown 
in Table 5.
Table 5. Correlation between cytokine level and FEV1. 
BAL: bronchoalveolar lavage GMSCF: granulocyte macrophage colony-stimulating factor, IFN: 
interferon; IL: interleukin; TNF: tumor necrosis factor
Discussion
Our study found significantly elevated levels of twelve cytokines 
and chemokines in the systemic circulation of subjects with 
COPD in comparison with non-COPD controls. In the BAL, 
cytokine levels were not different in COPD and non-COPD, 
except for TNF-α, which levels were elevated in the non-
COPD group. COPD is associated not only with an abnormal 
inflammatory response of the lung parenchyma but also with 
systemic inflammation implicated in the pathogenesis of many 
of the comorbidities linked to this condition including weight 
loss, skeletal muscle dysfunction, cardiovascular disease, 
depression, and osteoporosis, making this a popular study 
subject. Known mechanisms of local inflammation in COPD 
include oxidative stress, activation of resident inflammatory 
cells and increased production of proinflammatory cytokines. 
In local immune (e.g. macrophages) and non-immune cells 
(e.g. epithelial cells), it is known that cigarette smoke and air 
pollutants are triggers for these local mechanisms. On the other 
hand, the origin of systemic inflammation in COPD is not yet 
completely elucidated. The hypothesis that inflammatory cells 
“spill-over” into the systemic circulation has been explored, 
however, it has not been proven [20–22]. Smoking, per se, has 
been explored as a mechanism for systemic inflammation in 
COPD. Some cytokines appear to be elevated as a consequence 
of smoking, particularly, IFN-γ, TGF-b, IL-8 and MCP-1 [14]. 
The inflammatory process, however, seems to continue despite 
smoking cessation. This is supported by evidence of persistent 
presence of inflammatory cells and mediators and continued - 
despite slower - deterioration of lung function in ex-smokers [6, 
7, 23, 24].
Similarly to our findings, elevated levels of several cytokines in
the systemic circulation of COPD subjects have been previously
demonstrated in multiple studies. Some of the cytokines 
commonly found to be elevated were IL1-b, IL-6, IL-16, IL-8, 
TNF-α and VEGF [11, 14–16, 23, 25]. Selvarajah et al. measured 
fourteen cytokines in serum from never-smokers, ex-smokers, 
current smokers, and COPD subjects (GOLD stages 1-3) and 
found that the combined - not individual - increase of certain 
cytokines in COPD subjects was associated with disease 
severity, indicating that patterns of cytokine expression might 
be more relevant [14]. Aaron et al. measured sputum and 
serum cytokine levels in past and current smokers with COPD, 
smokers with no COPD, and non-smokers with COPD in three 
different occasions. Systemic and sputum biomarkers were 
associated with clinical variables that predict severity in COPD, 
but also showed a high degree of intra-subject variability by 
using repeated biomarker measurements over time, suggesting 
that one-time measurements may not be diagnostically reliable. 
As previously mentioned, the association between severity 
of disease and cytokine levels has been explored [14–16, 23]. 
According to GOLD guidelines FEV1/FVC is used for diagnosis 
of COPD and FEV1 is used to classify severity of disease [1]. In 
our study, we found significant negative correlation between 
levels of nine plasma cytokines and FEV1/FVC and three 
cytokines and FEV1.
We also measured cytokine levels in BAL fluid and surprisingly 
found none of the cytokines or chemokines to be significantly 
elevated in COPD subjects in comparison with non-COPD. 
In fact, level of TNF-α was found to be elevated in the non-
COPD group. Before we explore these findings, it is important 
to highlight that most studies exploring local inflammation 
in COPD have utilized induced sputum and not BAL samples 
as we were able to perform in our study. In addition, many of 
the studies using BAL measurements were conducted with the 
purpose of comparing local cytokine profiles in COPD versus 
asthma and not necessarily with the aim of contrasting BAL with 
serum levels such as we aimed with our analysis. Therefore, we 
consider that our study took a distinct approach when seeking a 
better understanding of inflammation in COPD, enabling one to 
compare BAL (local) versus plasma (systemic) in COPD versus 
non-COPD subjects.
Multiple studies have previously explored local inflammation 
in COPD by analysis of induced sputum with measurement 
of different cytokine levels. The findings have been overall 
inconsistent when sputum or BAL levels were compared to 
serum levels, as well as when levels were compared between 
COPD and non-COPD groups [9, 12, 15, 23, 26, 27]. Considering 
that we found low levels of locally present cytokines in COPD 
- which differs from most studies in our literature search - we 
bring the following points to discussion. First, inflammation 
in the setting of COPD may not originate and/or perpetuate in 
the lungs. As mentioned above, previous studies have shown 
that some COPD subjects continue to have decline in lung 
function despite smoking cessation [6, 7, 23, 24]. This suggests 
that inflammation in COPD could be generated systemically 
and not locally, which could potentially, or at least partially, 
explain the fact that to this day we have not found effective local 
therapies that prevent decline in lung function and significantly 
decrease morbidity and mortality in COPD. Second, BAL fluid 
may not be the optimal source of information when evaluating 
inflammation in COPD and selecting the correct biological fluid 
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Correlation (BAL) P-value Correlation (Plasma) P-value
GMSCF 0.319 0.048 -0.206 0.209
FRACTALKINE 0.184 0.262 -0.438 0.005
IL-12p70 0.061 0.713 -0.455 0.004
IL-17A 0.022 0.892 -0.325 0.043
IL-2 -0.085 0.606 -0.343 0.033
IL-21 0.108 0.514 -0.363 0.023
IL-6 -0.007 0.966 -0.389 0.014
IL-7 0.073 0.658 -0.442 0.005
IL-8 -0.124 0.451 -0.518 0.001
TNFα 0.426 0.007 -0.540 <0.001
 Correlation (BAL) P-value Correlation (Plasma) P-value 
GMSCF 0.454 0.004 0.063 0.701 
FRACTALKINE 0.159 0.334 -0.360 0.024 
IFNγ 0.353 0.027 -0.141 0.390 
IL-17A 0.345 0.031 -0.147 0.372 
IL-8  -0.026 0.877 -0.576 <0.001 
TNFα 0.367 0.021 -0.469 0.003 
is crucial in the search for targeted therapies.
Our study has several limitations including a small sample size
of sixty-five subjects and measurements coming from a one-time
isolated sample. It has been previously demonstrated that many
biomarkers that are apparently associated with COPD exhibit a
high degree of intra-subject variability [15]. Therefore, 
measuring cytokine levels at different time points and analyzing 
patterns of concomitantly elevated cytokines in certain groups 
would be an optimal approach. As subjects in the COPD group 
were overall older, another limitation of our study is the fact 
that our data analysis was not adjusted for age. It is known 
that aging is accompanied by immune changes leading to a 
chronic inflammatory state with potential increase in levels of 
inflammatory cytokines [28]. This was a pilot study with a small 
sample size, consequently with not enough power to conduct 
an analysis adjusted for age. Another potential confounder to 
be mentioned is the increased incidence of pneumonia in the 
COPD group, which could alter the inflammatory profile of these 
subjects leading to increased levels of inflammatory cytokines 
[29].
Strengths of our study include the ability of obtaining plasma 
and BAL fluid samples in an outpatient basis, when subjects were 
not currently experiencing or being treated for an exacerbation. 
In addition, the control and study populations were for the most
part similar. Finally, our analysis differs from most studies in 
this field by the fact that we were able to collect standardized 
bronchoscopic BAL fluid samples and not only induced sputum
samples for measurement of cytokine levels and comparison 
with plasma. Understanding in detail the local and systemic 
inflammatory processes of COPD is essential to elucidate 
the mechanisms that could potentially be altered. Our study 
identified elevated levels of several inflammatory cytokines 
in the plasma of COPD subjects when compared to controls, 
implying and supporting the role for systemic inflammation in 
this condition. Locally measured cytokine levels in the BAL were 
not elevated, suggesting that inflammation in COPD may not 
originate or not perpetuate in the lungs. In addition, the BAL 
may not be an optimal source of information when evaluating 
inflammation in COPD.
It is well known that COPD is a global epidemic and there is a 
major need for therapies that stop the decline in lung function 
and substantially decrease morbidity and mortality. Apart 
from the obvious large need for smoking cessation, ideal 
therapy would be the one targeting the underlying processes 
that progressively and continuously drive damage. Systemic 
anti-cytokine therapy might be part of a future solution in 
modulating inflammation and perhaps improving outcomes in 
this condition of great health burden. COPD is a very complex 
heterogeneous condition and so is the research needed to 
explore it. We suggest future large population studies that take 
into consideration patterns of plasma cytokine level elevation 
with measurements at different time points. Such approach 
could lead us to potential answers regarding which cytokines or 
their receptors to target and in which populations.
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